SAN DIEGO–(BUSINESS WIRE)–. Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost three times more than previously available on Illumina’s mid-throughput NextSeq sequencing portfolio, expanding... Read more
Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relations Japanese... Read more
Non-invasive sample collection and batch processing to test symptomatic and asymptomatic individuals – a breakthrough in COVID-19 testing WALTHAM, Mass.–(BUSINESS WIRE)–Nov. 12, 2020– PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five specimens... Read more
An interview with a professor passionate about clinical microscopy of urine sediments You might have seen the beautiful urinalysis imaging of Dr. José Antonio Tesser Poloni on his Twitter feed. Dr. Poloni is well established in the field of urinalysis. He is a professor of laboratory medicine specializing in disciplines related to clinical microscopy, such... Read more
Venlo, the Netherlands, November 11, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has commenced a share repurchase of up to $100 million as authorized in a repurchase program already announced on May 6, 2019. In the period between today and December 17, 2020, at the latest, up to $100 million of... Read more
MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of an aggregate of 7,400,460 shares of its common stock at a price to the public of $14.25 per share. Pacific Biosciences... Read more
MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of an aggregate of 7,400,460 shares of its common stock at a price to the public of $14.25 per share. Pacific Biosciences... Read more
LOW COST, HIGH-SENSITIVITY DIAGNOSTIC TEST FOR COVID-19 DETECTION Zymo Research was recently granted the CE IVD certification for its Quick SARS-CoV-2 Multiplex Kit. IRVINE, Calif., (Nov. 10, 2020) — Zymo Research announced today that it obtained a CE IVD mark for the Quick SARS-CoV-2 Multiplex Kit in compliance with the Directive 98/79/EC of the European Parliament and of... Read more